Similar Efficacy and Safety Seen Between Under-the-Skin Formulation and Intravenous Darzalex for Myeloma, Phase 3 Trial Shows
An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable…